Since Pi Day fell on Saturday this year (3/14), Arrakeens celebrated early! We provided the pizza “pie" and team members brought in their favorite pies for dessert (so many flavors!) to help us contemplate the value of pi.
#PiDay #PiDay2026 #ArrakeensInAction
Today at the Muscular Dystrophy Association Clinical & Scientific Conference, Domi Stickens, PhD, CSO, presents a poster highlighting our RNA-targeted small-molecule therapeutics and first oral therapy in development for myotonic dystrophy type 1 (DM1).
#MDAconference #ArrakeensInAction
Today at the RNA Targeted Drug Discovery Summit, CSO Domi Stickens PhD will present on our lead oral RNA-targeted small molecule (rSM) drug program for myotonic dystrophy type 1 (DM1). We plan to advance this rSM to an IND filing in 2026.
arrakistx.com/press-releas...
#ArrakeensInAction #BioSky
This week we’ll be at the RNA Targeted Drug Discovery Summit in Boston. CSO Domi Stickens will present on our RNA-targeted small molecule (rSM) drug program for myotonic dystrophy type 1 (DM1), and Founder & CSO Emerita Jennifer Petter shares her expertise on two panels.
#ArrakeensInAction #BioSky
The Arrakis team gathered to volunteer at Waltham Fields Community Farm, helping with weeding and preparing their fall harvests. We’re glad to support the Farm, its educational programs, and the food it produces for the Waltham community.
#ArrakeensInAction
At the Discovery on Target: RNA and DNA Targeting Small Molecule Drugs conference in Boston today, Emily, Associate Director, Medicinal Chemistry, presents on our proprietary platform to develop RNA-targeted small molecule (rSMs) medicines.
#ArrakeensInAction
At the Computational Medicinal Chemistry School hosted by Novartis today in Cambridge, Aaron, Director of Computational Chemistry, shares his expertise on biomolecular modeling. #drugdiscovery #ArrakeensInAction
Today our Founder and CSO Jennifer Petter, PhD joins other inspiring panelists to discuss leading with confidence and authenticity at a Harvard course for LGBTQ+ professionals.
#ArrakeensInAction
Last week we joined Xilio Therapeutics and Q32 Bio to celebrate #PrideMonth with our Waltham Biotech Pride Mix & Mingle, and we collected donations of essential items for The Waltham House LGBTQ+ youth group home.
Learn more: www.thehome.org/programs/wal...
#ArrakeensInAction
Two Arrakeens are sharing their expertise at the 5th Annual Induced Proximity-Based Drug Discovery Summit in San Diego this week. Craig presents on our work targeting RNA, and Aaron leads a workshop on AI-driven co-folding. #ArrakeensInAction
A team of Arrakeens participated in the J.P. Morgan Corporate Challenge this week for the annual 3.5-mile road race. We were proud to run in support of the Ron Burton Training Village, whose mission is to train youth to achieve their purpose with a range of programs. #ArrakeensInAction #JPMCC
This week the Arrakis team volunteered at Healthy Waltham, an organization working to improve the health outcomes of Waltham’s most vulnerable residents through access to healthy foods, nutrition education and opportunities for physical activity. We’re inspired by their mission.
#ArrakeensInAction
Today at the 2nd Biophysics for Drug Discovery Summit in Boston, Griffin Schroeder, Scientist II, will present on our work to target RNA for new small molecule (rSM) medicines. #ExpeditionRNA #ArrakeensInAction
Today, Kathleen McGinness, PhD, our VP of Platform Biology, will present on our work to target RNA for new small molecule (rSM) medicines at the CHDI 20th Annual Huntington’s Disease Therapeutics Conference in Palm Springs, CA. #ExpeditionRNA #ArrakeensInAction
